TPP-1 peptide

TPP-1 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-SGQYASYHCWCWRDPGRSGGSK-OH

H-Ser-Gly-Gln-Tyr-Ala-Ser-Tyr-His-Cys-Trp-Cys-Trp-Arg-Asp-Pro-Gly-Arg-Ser-Gly-Gly-Ser-Lys-OH

22

95.19%

C₁₀₇H₁₅₀N₃₄O₃₂S₂

2488.66

Synthetic

Powder

TPP-1 is a peptide identified through bacterial surface display which binds specifically to programmed cell death ligand 1 (PD-L1), and blocks programmed cell death protein 1 (PD-1)/PD-L1 interaction. TPP-1 binds to free PD-L1 and also cells that express PD-L1 on their cell membranes, and can reverse PD-L1 mediated inhibition of T-cell activation, and inhibit human tumour growth via a T-cell–dependent mechanism. In xenograft mouse models, tumour growth in TPP-1 treated mice was 56% - 71% lower than that in controls.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Li et al (2018) Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 6(2) 178 PMID: 29217732

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.